one:imatinib

3 trials

Sponsors

Peking University People's Hospital, Peking University Institute of Hematology, Peking University People's Hospital

Conditions

Chronic myeloid leukemiachronic myelogenous leukemia

Phase 1

The quality of life and toxisities in patients with chronic myeloid leukemia during imatinib therapy

Active, not recruitingChiCTR-ONC-11001698

Peking University People's Hospital, Peking University Institute of HematologyChronic myeloid leukemia

Start: 2001-04-24Updated: 2017-04-18

The correlations of the cytogenetic responses and the molecular responses during imatinib therapy for chronic myelogenous leukemia

Active, not recruitingChiCTR-ONC-11001697

Peking University People's Hospitalchronic myelogenous leukemia

Start: 2006-03-01Updated: 2017-04-18

Phase 3

The comparative study of quality of life and toxisities in patients with chronic myeloid leukemia during imatinib therapy vs. nilotinib therapy

Active, not recruitingChiCTR-OCH-11001699

Peking University People's Hospital, Peking University Institute of HematologyChronic myeloid leukemia

Start: 2011-05-01Updated: 2017-04-18

Related Papers

Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study

BMC Cancer2018-08-0313 citations